BMYBristol Myers Squibb

Healthcare

$59.11+34% 1Y

$59.11

$41.6752 weeks$68.08

Is it safe?

Good

Strong, no red flags: clean books and quality strong.

2 good, 3 neutral, 1 without data

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality8 / 9

High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$437K

Insiders were net sellers (-$437K, 90 days to Oct 8, 2026), selling is often routine.

Credit gradeBBBderived · Jun 30, 2026

Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.

Drawdown risk28% volderived · Oct 9, 2026

Moderate price swings, typical volatility. Worst drawdown -48% · now 13% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybetter than 80% of the market

Max drawdownbetter than 81% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can BMY take a bad year?

Bristol Myers Squibb carries $32.8B of net debt at 2.38× EBITDA: a load its earnings can carry.

$32.8B

Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable

Net debt / EBITDA: 2.38×
Net debt / EBITDA · 4.08× a year ago · the load is coming down
Interest cover: 6.88×
Interest cover · operating profit covers the interest bill several times over
Annualised volatility: 28%
Annualised volatility · about as steady as the market itself